.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean follow-up of 11 months, individuals along with metastatic gastrointestinal lumps that got biomarker-matched treatments based upon circulating cyst DNA profiling presented a better medical advantage than those obtaining unrivaled therapy.